Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Holy Name Hospital — Teaneck, New Jersey
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in New Jersey: - MSK Basking Ridge — Basking Ridge, New Jersey
- MSK Monmouth — Middletown, New Jersey
- MSK Bergen — Montvale, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey ( Site 0033) — New Brunswick, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Sponsor: Celgene
NCT ID: NCT06764485
Sites in New Jersey: - Thomas Jefferson University, Kennedy Health Alliance — Sewell, New Jersey
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016) — Hackensack, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in New Jersey: - Astera Cancer Care — East Brunswick, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in New Jersey: - Atlantic Health System Morristown Medical Center ( Site 0115) — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 0033) — New Brunswick, New Jersey
Phase 3 Recruiting Industry
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Sponsor: Curium US LLC
NCT ID: NCT06235151
Sites in New Jersey: - United Theranostics — Princeton, New Jersey
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in New Jersey: - Research Site — Hackensack, New Jersey
- Research Site — Voorhees Township, New Jersey
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in New Jersey: - New Jersey Urology LLC — Voorhees Township, New Jersey
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in New Jersey: - East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ — East Orange, New Jersey
Phase 3 Recruiting Academic/Other
In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07548164
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 3 Recruiting Academic/Other
The purpose of this study is to look whether using local anesthesia during a transperineal prostate biopsy, while put to sleep by IV sedation, helps reduce the number of people who feel significant pain in the recovery room. The researcher…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06986083
Sites in New Jersey: - Memorial Sloan Kettering Cancer Center at Basking Ridge (Consent Only) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only) — Montvale, New Jersey
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
Phase 1, Phase 2 Recruiting Industry
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main p…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05125016
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Sponsor: AstraZeneca
NCT ID: NCT06267729
Sites in New Jersey: - Research Site — Hackensack, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back afte…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07111507
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Industry
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…
Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in New Jersey: - Summit Health — Saddle Brook, New Jersey
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating pati…
Sponsor: Eikon Therapeutics
NCT ID: NCT07262619
Sites in New Jersey: - Morristown Medical Center — Morristown, New Jersey
Phase 2 Recruiting Academic/Other
Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria fo…
Sponsor: Hackensack Meridian Health
NCT ID: NCT06798558
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with adv…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT04729114
Sites in New Jersey: - Garden Sate Urology — Morristown, New Jersey
Phase 1 Recruiting Industry
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Sponsor: SystImmune Inc.
NCT ID: NCT07080242
Sites in New Jersey: - John Theurer Cancer Center-Hackensack — Hackensack, New Jersey
- Rutgers Cancer Institute — New Brunswick, New Jersey
Phase 1 Recruiting Industry
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered…
Sponsor: Exelixis
NCT ID: NCT05932862
Sites in New Jersey: - Exelixis Clinical Site #9 — New Brunswick, New Jersey
Phase 1 Recruiting Industry
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of t…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06095089
Sites in New Jersey: - START New Jersey — East Brunswick, New Jersey